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To determine which efflux carriers are involved in hepatic phalloidin elimination, hepatobiliary [3H]-demethylphalloin (DMP) excretion was
studied in normal Wistar rats and in Mrp2 deficient TR(−) Wistar rats as well as in normal wild-type FVB mice, Mdr1a,b(−/−) knockout mice, and
Bcrp1(−/−) knockout mice by in situ bile duct/gallbladder cannulation. A subtoxic dose of 0.03 mg DMP/kg b.w. was used, which did not induce
cholestasis in any tested animal. Excretion of DMP into bile was not altered in Mdr1a,b(−/−) mice or in Bcrp1(−/−) mice compared with wild-type
FVB mice. Whereas 17.6% of the applied dose was excreted into bile of normal Wistar rats, hepatobiliary excretion decreased to 7.9% in TR(−)
rats within 2 h after intravenous application. This decrease was not due to reduced cellular DMP uptake, as shown by normal expression of
Oatp1b2 in livers of TR(−) rats and functional DMP uptake into isolated TR(−) rat hepatocytes. Tissue concentrations of phalloidin were also not
altered in any of the transgenic mice. Interestingly, the decrease of biliary DMP excretion in the TR(−) rats was not followed by any increase of
phalloidin accumulation in the liver but yielded a compensatory excretion of the toxin into urine, indicating that hepatocytes of TR(−) rats
expelled phalloidin back into blood circulation.
© 2007 Elsevier B.V. All rights reserved.1. Introduction
Phallotoxins are bicyclic heptapeptides from certain Amanita
mushroom species [1]. Poisoning by the toxin phalloidin from the
Amanita phalloides mushroom (the “Green Death Cap”) causes
selective toxicity to liver parenchymal cells due to a selective
carrier-mediated toxin uptake into hepatocytes [2–4]. In the liver,
phalloidin provokes cholestasis by microfilament disturbances,
i.e. by preventing F-actin from depolymerizing [5–9].
In the late 1970s, we showed that physiological concentra-
tions of bile acids inhibited this uptake and the toxic response of
rat hepatocytes to phalloidin [10,11]. Further in vitro experi-
ments carried out with various drugs and reagents (rifampicin,Abbreviations: DIDS, diisothiocyanostilbenedisulfonat; DMP, Demethyl-
phalloin; OATP/Oatp, human/rat Organic anion transporting polypeptide; Oct,
Organic cation transporter; Oat, Organic anion transporter; MRP/Mrp, human/
rat multidrug resistance-associated protein; Mdr1, mouse multidrug resistance
protein; Bcrp, mouse breast cancer resistance protein; Bsep, Bile salt export
pump; TR(−), transport-deficient rat
⁎ Corresponding author. Tel.: +49 641 9938400; fax: +49 641 9938409.
E-mail address: ernst.petzinger@vetmed.uni-giessen.de (E. Petzinger).
0005-2736/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2007.07.006bromosulfophthalein, DIDS, silymarin) demonstrated that all
agents that decreased the uptake of [3H]-demethylphalloin
([3H]-DMP) (a radioactive surrogate compound of phalloidin)
in hepatocytes also inhibited the accumulation of bile acids in a
comparable manner [11–13]. Based on these data, we pos-
tulated that phalloidin is taken up into hepatocytes by a
multispecific hepatic bile acid transporter [14,15].
Fifteen years later, several organic anion transporting poly-
peptide (OATP) carriers were cloned, which showed over-
lapping transport activities for a broad spectrum of physiological
substrates (bile acids, eicosanoids, steriod hormones), drugs
(digoxin, CRC220, pravastatin, fexofenadine), and toxins
(ochratoxin A), as reviewed by Hagenbuch and Meier in
2003 [16]. Recently, rat Oatp1b2 and human OATP1B1 and
OATP1B3, which are highly expressed in the basolateral
membrane of hepatocytes [17–19], were shown to transport
phalloidin with a Km of 5.7–39 μM from blood into hepatocytes
[20,21]. In vitro evidence was obtained that human MRP2
might be involved in canalicular phalloidin excretion [20]. In
this report on in vivo experiments with transporter deficient rats
and mice, we show that rat Mrp2 is the main export carrier for
phalloidin excretion into bile.
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2.1. Animals and [3H]-DMP application
Male Mdr1a,b(−/−) and Bcrp1(−/−) knockout mice (body weight 26–41 g)
were obtained from Taconic Farms Inc. (Germantown, NY, USA). The mice
were between 20 and 24 weeks of age. All mice were housed in microisolator
units and were provided with sterilized food and water. Male Wistar and Mrp2-
deficient TR(−) rats were inbred and kept in our animal facility according to
governmental regulations. They were experimented upon at an age of about 4
months (body weight 300–450 g). The animal experiments were registered with
the local government and approved by them. All experiments were performed
under general anesthesia. [3H]-DMP (spec. activity 2 Ci/mmol) [22] was gen-
erously donated by Prof. Dr. H. Faulstich [21]. For all experiments, [3H]-DMP
was dissolved in phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl,
1.5 mMKH2PO4, 7.3 mMNa2HPO4, pH 7.4) and injected into the femoral (rats)
or tail (mice) vein at a dose of 0.03 mg/kg of body weight.
2.2. Gall bladder cannulation
Mice were anesthetized with a combination of ketamine and xylazine at a
final dose of 116 mg/kg ketamine and 8 mg/kg xylazine. The anesthetic solution
was injected i.p. After laparatomy and distal ligation of the common bile duct, a
polyethylene catheter with an inner diameter of 0.25 mm was inserted into the
incised gall bladder and was fixed to the gall bladder with an additional ligation.
After i.v. injection of [3H]-DMP, bile was collected over a 90-min time period,
during which the mice were placed in a temperature-controlled hood.
2.3. Bile duct cannulation
Male Wistar rats and TR(−) rats were anaesthetized by intraperitoneal
application of 1.5 g/kg urethane as an 20% aqueous solution. After laparatomy,
the bile duct was catheterized by a teflon tube (0.3×0.6 mm inner/outer
diameter), fixed with an additional ligation, and the urinary bladder was
cannulated with a teflon catheter also. After i.v. injection of [3H]-DMP (0.03 mg/
kg b.w.), bile and urine were collected for 120 min.
2.4. Bile sample collection
The total volume of bile after 90 min (mice) or 120 min (rats) was: 153
±41 μl per mouse, 719±253 μl per TR(−) rat, and 1572±327 μl per Wistar
rat. At the end of the experiments, blood was collected by cardiac puncture,
and the organs were removed and homogenized in 100–7000 μl 0.05 M
NaOH (depending on the tissue weight). The levels of radioactivity in serum,
bile, urine, faeces, and tissue homogenates were quantified by a Wallac 1409
liquid scintillation counter.
2.5. Thin-layer chromatography
Thin-layer chromatography of [3H]-DMP-containing bile was performed
according to Puchinger and Wieland [23] with some modifications. TLC plates
60 F254, 0.2 mM thick, were used (Merck, Darmstadt, Germany). The solvent
contained CHCl3, MeOH, and water (48:48:4 vol/vol). The TLC chambers were
saturated with vaporized solvents before each run. The radioactivity of TLC
peaks was measured under argon/methane (90:10 vol/vol) atmosphere by a TLC
analyzer IM 3000 (Isomess, Straubenhardt, Germany).
2.6. Transport experiments in isolated hepatocytes from TR(−) rats
Isolated rat hepatocytes were prepared by an enzymatic collagenase digestion
method as previously described [10,11]. In brief, hepatocytes in suspension were
washed three times with Tyrode-buffer to remove debris and finally pelleted by
centrifugation at 50×g. After pre-incubation in glucose-supplemented Tyrode
buffer for 30 min, transport measurements were performed in a shaking water
bath at 37 °C under carbogen atmosphere (95% O2/ 5% CO2). A mixture of
12.5 nmol phalloidin (cold) plus 0.65 nmol [3H]-DMP (1.3 μCi) was added to 2 ml
of cell suspension containing 2 to 4×106 cells/ml. In parallel, inhibition experimentswere performed in which cells were incubated in 100 μmol/l taurocholic acid for
30 s prior to the addition of phallotoxins. Aliquots of 100 μl were withdrawn from
the cell suspension at the following time intervals: 15 s, 45 s, 75 s, 105 s, 135 s,
3 min, 5 min, 10 min, 15 min, and 20 min. The aliquots were then pelleted by
centrifugation at 20,000×g through silicon oil into 3 M KOH as already described
[11]. Cell associated radioactivity was counted in the fluid-stripped cell pellets from
the centrifugation tube bottoms.
2.7. Real-Time Quantitative RT-PCR
cDNA was synthesized from 1 μg liver and 1 μg kidney RNAs of normal
Wistar rats (n=3) and TR(−) rats (n=3). Quantitative PCR expression analysis
was performed using ABI PRISM 7300 technology with the TaqMan Gene
Expression Assays: Rn00667869_m1 for β-actin, Rn00581304_m1 for
Oatp1b2, Rn00562250_m1 for Oct1, Rn00580893_m1 for Oct2,
Rn00568143_m1 for Oat1, Rn00580082_m1 for Oat3, Rn00589786_m1 for
Mrp3, Rn01465702_ml for Mrp4, Rn00561753_ml for Mdr1, Rn00710585_ml
for Bcrp, and Rn00582179_m1 for Bsep. The expression data of β-actin was
used as the endogenous control. Quadruplicate determinations were performed
for all targets in a 96-well optical plate using 5 μl cDNA, 1.25 μl TaqMan
Gene Expression Assay, 12.5 μl of TaqMan Universal PCR Master Mix, and
6.25 μl of water in each 25 μl reaction. The plates were heated for 5 min at
95 °C, and then 40 cycles of 15 s at 95 °C and 60 s at 60 °C were applied. The
relative carrier expression (ΔCT) was calculated by subtracting the signal thres-
hold cycle (CT) of the internal standard β-actin from the CT value of the
respective carrier. For each carrier, ΔCT values were determined from liver and
kidney samples of three Wistar rats and three TR(−) rats. Then ΔΔCT values
were calculated by subtracting theΔCT value of each carrier from theΔCT value
of renal Mdr1 (the carrier with the lowest expression level) and transformed by
the equation 2−ΔΔCT.
2.8. Statistical analysis
The data are presented as the mean±SEM of three to four animals. Student's
two-tailed unpaired t-test and one-way ANOVA followed by Bonferroni's post
hoc test were used to identify significant differences between groups.
3. Results
3.1. Bile flow data
At the applied low dose of 0.03 mg/kg b.w. [3H]-DMP, no
signs of cholestasis, i.e. reduced bile flow compared with non-
treated control animals, were observed (Fig. 1 and Table 1). This
indicates that phalloidin excretion into bile was not hampered by
the indirect effects on the cytoskeleton and liver microcircula-
tion that otherwise occur within 90 min after toxic phalloidin
concentrations of about 0.8–1 mg/kg b.w. [24,25]. The mean
bile flowwas 11–13 μl/min in normalWistar rats and 1.4–2.1 μl/
min in normal and transgenic mice (Table 1). Bile flow was
about 50% lower in TR(−) rats (5–6 μl/min) compared with
normal Wistar rats, as has been previously reported [26,27].
3.2. Hepatobiliary excretion of [3H]-DMP
After i.v. injection, hepatobiliary excretion of [3H]-DMP was
rapidly detected within a few minutes in rats and mice. The
maximal flux of [3H]-DMP excretion was 0.14 pmol/min/g b.w.
at 16 min in FVB mice, 0.11 pmol/min/g b.w. at 20 min in
Mdr1a,b(−/−) knockout mice, and 0.15 pmol/min/g b.w. at
12 min in Bcrp1(−/−) knockout mice. The overall hepatobiliary
excretion of [3H]-DMP was not significantly different among
Fig. 2. Biliary excretion-time profiles of [3H]-DMP given intravenously at a
dose of 0.03 mg/kg b.w., (A) in FVB mice, Mdr1a,b(−/−) knockout-mice, and
Bcrp1(−/−) knockout mice, and (B) in Wistar rats and TR(−) rats. Data represent
means±SEM of three to four animals. ⁎ Significantly higher levels in Wistar rats
compared with TR(−) rats ( pb0.001).
Fig. 1. Bile flow after intravenous application of 0.03 mg/kg b.w. [3H]-DMP
during 90 min (mice, A) and 120 min (rats, B). Data represent means of 3
animals per group, COV=18 to 31%.
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strains (Fig. 2). Maximal biliary fluxes of [3H]-DMP excretion
in normal Wistar rats peaked at 0.24 pmol/min/g b.w. at 8 min
after i.v. application and dropped continuously to unmeasur-
able amounts after 2 h. By contrast, Mrp2-deficient TR(−) rats
exhibited significantly lower and delayed [3H]-DMP excretion
with the flux maximum at 0.07 pmol/min/g b.w. at the
30th minute (Fig. 2B). After 90 min of in situ bile sampling,
11.8% of the applied [3H]-DMP was recovered in FVB wild
type mice, 10.4% in Mdr1a,b(−/−) knockout mice, and 11.8%
in Bcrp1(−/−) knockout mice (Fig. 3A). The hepatobiliary
excretion of [3H]-DMP in the Mrp2-deficient TR(−) rats was
significantly lower compared to Wistar rats when analyzed
by a cumulation graph. Whereas 17.6% of the total dose
of [3H]-DMP was recovered from bile within 120 min in
normal Wistar rats, this value reached 7.9% on TR(−) rats
(Fig. 3B).Table 1
Bile flow data
Bile Mice Rats
Wild type
FVB
Mdr1a,b
(−/−)
Bcrp1
(−/−)
Wistar TR(−)
Without [3H]-
DMP
1.80±0.39 1.44±0.44 2.14±0.49 13.02±3.14 6.04±1.82
With [3H]-
DMP
1.75±0.63 1.51±0.36 1.81±0.36 10.77±2.20 5.32±1.22
The data are shown as means±SEM in μl/min.
Fig. 3. Cumulative biliary excretion-time profiles of [3H]-DMP given
intravenously at a dose of 0.03 mg/kg b.w., (A) in FVB mice, Mdr1a,b(−/−)
knockout mice, and Bcrp1(−/−) knockout mice, and (B) in Wistar rats and TR
(−) rats. Data represent means±SEM of three to four animals. ⁎ Significantly
lower levels in TR(−) rats compared to Wistar rats ( pb0.001).
Fig. 4. Quantitative real-time RT-PCR analysis of Oatp1b2, Oct1, Oct2, Oat1, Oat3, Mrp3, Mrp4, Mdr1, Bcrp, and Bsep expression in liver and kidneys of normal
Wistar rats and TR(−) rats. Relative carrier expression shown at the y-axis was calculated by 2−ΔΔCT transformation. Data were calculated from quadruplicate carrier
mRNA determinations from livers and kidneys of three Wistar and three TR(−) rats and represent means±SEM. ⁎ Significantly higher expression in TR(−) rats
compared with Wistar rats ( pb0.05).
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TR(−) rats
Oatp1b2 is the hepatic uptake carrier for phalloidin in rats,
and Mrp3 and Mrp4 are candidates for phalloidin efflux from
hepatocytes. So we analyzed hepatic expression of these carriers
with real-time quantitative PCR. Oct1, Oct2, Mdr1, Bcrp, and
Bsep were included in the PCR analysis for comparison. The
results presented in Fig. 4 show that the expression of Oatp1b2,
Oct1, Oct2, Mdr1, Bcrp, and Bsep was not altered, but Mrp3 and
Mrp4 expression was significantly higher in the liver of TR(−)
rats compared with normal Wistar rats.Fig. 5. Detection by TLC of [3H]-DMP in the bile of rats. Bile samples collected fro
application of [3H]-DMP were applied on TLC-plates along with bile from Wistar
(control). The chromatograms show identical location (Rf) of the major peaks in eac3.4. Relative carrier expression in the kidney of Wistar rats and
TR(−) rats
Since we observed markedly higher excretion of [3H]-DMP
into urine of TR(−) rats compared with Wistar rats (see below)
the relative mRNA expression of the carriers Oct1, Oct2, Oat1,
Oat3, Mrp3, Mrp4, Mdr1, and Bcrp was analyzed in rat kidneys.
In contrast to the liver, no significant alteration in carrier mRNA
expression was found in kidneys from both rat strains (Fig. 4)
indicating that the mutation in the Mrp2 gene of TR(−) rats only
involves compensatory carrier upregulation in the liver but not
in the kidney.m TR(−) rats and Wistar rats between t=55 and t=60 min (Δ 5 min) after i.v.
rats that had been spiked with a comparable amount of radioactive [3H]-DMP
h bile sample.
Table 2
Tissue concentrations of [3H]-DMP in wild type FVB mice, Mdr1a,b(−/−) knockout mice, and Bcrp1(−/−) knockout mice, and in Wistar rats and TR(−) rats, 90 min
(mice) or 120 min (rats) after i.v. injection of a dose of 0.03 mg/kg b.w.
Tissue Mice Rats
Wild type FVB Mdr1a,b(−/−) Bcrp1(−/−) Wistar TR(−)
Liver 148.54±8.87 172.73±34.54 266.09±64.96 297.05±4.50 285.90±22.74
Small intestine 9.37±0.17 11.44±0.43 11.25±2.38 11.56±3.73 25.33±1.92
Colon 5.08±0.81 7.14±0.95 9.58±3.12 7.62±2.22 15.73±3.81
Kidney 136.55±32.57 98.58±22.94 148.65±55.44 128.38±47.65 489.61±117.45*
Stomach 6.95±1.53 9.94±0.65 8.15±1.79 8.84±0.98 21.18±1.63
Spleen 8.70±0.49 12.96±0.63 16.84±2.34 11.57±0.50 16.19±5.17
Testis 7.26±1.39 5.96±0.18 6.62±1.12 6.36±0.23 11.53±2.23
Heart 5.78±0.44 9.30±1.96 8.52±1.14 7.88±1.03 6.76±1.25
Lung 9.34±1.07 17.38±1.37 10.94±1.03 8.32±2.32 16.79±2.41
Brain 2.62±0.04 3.30±0.06 3.16±0.10 2.34±0.04 3.36±0.27
Plasma 0.018±0.003 0.017±0.003 0.027±0.004 0.028±0.003 0.049±0.014
Skeletal muscle 5.68±1.33 2.63±0.36 4.72±0.35 7.15±5.54 5.67±2.46
Abdominal fat 12.38±0.64 10.97±0.73 12.71±2.76 8.17±2.59 12.19±1.81
Values represent means±SEM in pmol [3H]-DMP per gram of tissue and per ml of plasma. ⁎ Significantly higher levels in TR(−) rats compared to Wistar rats ( pb0.05).
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In order to analyze compound identity and metabolism of
excreted [3H]-DMP in rat bile, thin-layer chromatography
according to Puchinger and Wieland [23] was performed with
all collected bile samples. To enable direct comparison, the
applied volume of bile was standardized in such a way that an
equal amount of sample radioactivity was placed on each lane on
the TLC-plate. Neither normal Wistar rats nor Mrp2-deficient
TR(−) rats metabolized radioactive demethylphalloin (Fig. 5).
3.6. Tissue concentration and urinary excretion of [3H]-DMP
When in situ bile sampling of [3H]-DMP was finished, mice
were killed at t=90 min and radioactivity was measured in
various organs. At this time point, the livers and kidneys of FVB-
wild type mice contained 16.5% and 5.3% of the applied dose of
[3H]-DMP, respectively. Comparable results were found in both
knockout mice strains: 17.2% and 4.1% inMdr1a,b(−/−) knock-Fig. 6. Urinary excretion of [3H]-DMP in rats and mice. (A) Urine concentration after
TR(−) rats, and gall bladder cannulated FVB mice, and Mdr1a,b(−/−) and Bcrp1(−/−
90 min in mice. Bars represent means±SEM of three individual animals. ⁎ Significant
(B) Cumulative urine excretion in Wistar rats and TR(−) rats over a total time perioout mice, and 20.9% and 5.1% in Bcrp1(−/−) knockout mice,
respectively. In all other organs and in plasma, only low con-
centrations of [3H]-DMP were detected, and they showed no
differences among the tested mice strains (Table 2).
The organ distribution of [3H]-DMP-derived radioactivity at
t=120 min in TR(−) rats and normal Wistar rats yielded similar
levels in the livers, at 25.3% and 28.8%, respectively. In contrast,
[3H]-DMP-derived radioactivity was significantly higher in the
kidneys of TR(−) rats compared with normal Wistar rats, being
9.9% vs. 2.9% of the applied dose, respectively (Table 2). The
tissue concentrations of [3H]-DMP in all other organs from TR
(−) rats were not elevated compared with normal Wistar rats. At
the end of experiments, the plasma concentrations of [3H]-DMP
were 1.8 times higher in TR(−) rats than in Wistar rats. TR(−)
rats excreted 8.4% of the applied [3H]-DMP dose into the urine,
in contrast to Wistar rats, where this excretion was almost nil
(Fig. 6A). This difference was though not caused by different
amounts of urine collected over the time period of 120 min
(Fig. 6B). Similar to TR(−) rats but in contrast to Wistar rats,[3H]-DMP application (0.03 mg/kg b.w.) in bile duct cannulated Wistar rats and
) knockout mice. Urine was collected for a total period of 120 min in rats and of
ly higher [3H]-DMP concentration in TR(−) compared to Wistar rats ( pb0.001).
d of 120 min.
Fig. 7. Transport of [3H]-DMP into isolated hepatocytes of TR(−) rats. Freshly
prepared hepatocytes were incubated at cell density of 2 to 4×106/ml in the
presence of a mixture of 6.6 μmol/l phallotoxins (6.25 μmol/l phalloidin plus
0.33 μmol/l [3H]-DMP) at 37 °C under carbogen atmosphere. At time intervals
indicated, cell aliquots were subjected to centrifugation through silicon oil and
cell associated radioactivity was determined. In parallel phallotoxin uptake was
measured in cells to which taurocholic acid was added at 100 μmol/l
concentration 30 s prior to the addition of [3H]-DMP plus phalloidin. Data
represent means±SEM of three cell preparations. ⁎ Significantly reduced uptake
into hepatocytes after preincubation with taurocholic acid ( pb0.001).
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knockout mice excreted considerable amounts of [3H]-DMP
into the urine over 90 min (i.e. 16.7%, 11.2%, 9.7% of the
applied dose of [3H]-DMP, respectively) (Fig. 6A).
3.7. Transport studies with [3H]-DMP in isolated rat
hepatocytes from TR(−) rats
Mrp2-deficient TR(−) rats showed a marked decrease of
DMP excretion into bile. This loss of excretion was not due to
functionally impaired DMP uptake in the liver as revealed by
uptake measurement with isolated TR(−) rat hepatocytes (Fig.
7). The uptake of DMP from a mixture with phalloidin was
completely abolished if the TR(−) rat hepatocytes were exposed
to a 15.2 fold excess of the competitive uptake inhibitor tauro-
cholic acid, as was previously shown for phallotoxin uptake in
isolated Wistar rat hepatocytes [11,12]. This indicates that func-
tionally active Oatp1b2 carriers are present also in the plasma
membrane of TR(−) rat hepatocytes.
4. Discussion
The selective hepatotoxicity of phallotoxins is caused by their
organ-specific uptake into liver parenchymal cells. Previous
transport studies with phallotoxins have identified basolateral
phalloidin uptake carriers of hepatocytes (see Introduction).
Nonetheless, their transport across the canalicular cell mem-
brane into bile is not understood. Liver-toxic doses of phalloidin
exert strong cholestatic effects [28], due to its binding to
microfilamentous actin [6,29]. Under such circumstances, bile
formation ceases and hepatobiliary excretion of the toxin cannot
be investigated. Also, loss of several ABC-carriers at the cana-
licular membrane was observed under phalloidin-induced
cholestasis [30]. Furthermore, Ohashi et al. [31] reported that
phalloidin doses of 0.5 mg/kg, i.e. 17 times higher than that usedin our study, inhibited hepatic Mrp2, Bsep, and Mdr1 mediated
transport of marker substances. They observed a bile flow
reduction of 50–80% and a strong decrease of bile excretion of
taurocholic acid (a marker substrate for Bsep), LTC4 and
pravastatin (marker substrates for Mrp2), and vinblastine (a
marker substrate for Mdr1). Our study aimed to identify cana-
licular ABC-carriers involved in the hepatobiliary excretion of
phalloidin under conditions of normal bile flow. We applied a
non-cholestatic dose (0.03 mg/kg b.w.) of [3H]-DMP (an equally
toxic, radiolabeled derivative of phalloidin [32]) to rats and mice
which were deficient in specific canalicular ABC-transporters.
At this dosage we observed unaltered bile flow within the time
periods of 90 min in mice and of 120 min in rats.
The results with transporter-deficient mice showed that the
canalicular ABC-transporters Mdr1 and Bcrp do not transport
[3H]-DMP. Instead, Mrp2 is an efflux-pump of phallotoxin and
maintains a major part of the carrier-mediated secretion of [3H]-
DMP into bile. However, DMP was still found in bile of TR(−)
rats despite the loss of Mrp2-mediated excretion, and amounted
to almost 45% of the total DMP excretion within 120 min in
normal livers (7.9% versus 17.6% of the applied [3H]-DMP
dose). It remains to be confirmed, whether this phenomenon is
related to excretion by other canalicular carriers besides those
investigated here or whether it represents non-carrier mediated
transcytotic vesicular excretion. An estimate of vesicle-mediated
transcytosis in rat livers based on studies of the hepatobiliary
clearance of the fluid-phase marker inulin has suggested that this
pathway amounts to 6% to 8% of total bile production [33]
which is much lower than the relative percentage of that residual
DMP excretion in TR(−) rats. For this reason, we prefer to
assume an additional carrier-mediated step for this part of DMP
excretion in TR(−) rats. In a transgenic knockout-mouse model,
it could not be explicitly studied here whether this is excretion by
Bsep. Bsep is the main ABC-transport for the excretion of bile
acids but may also transport some non-bile acid substrates.
However, Loranger et al. [25] have reported a liver-toxic dose of
phalloidin (0.8 mg/kg b.w.) did not reduce bile acid secretion in
rats, even though it significantly lowered total bile flow. So the
canalicular Bsep carrier is not tackled by phalloidin in normal
rats. As Bsep is not upregulated in TR(−) rats (Fig. 4 and [34])
the bile salt export pump might not be relevant for [3H]-DMP
transport into bile. Our in situ data are in agreement with in vitro
results with double transfected MDCK cells, in which human
OATP1B1 was co-expressed with human MRP2 (ABCC2) [20].
Those authors concluded that MRP2 should be involved in
transepithelial phalloidin transport in humans.
Mrp2, Bcrp, and Mdr1 are known to play a pivotal role in the
excretion of xenobiotics into bile [35–39]. Mrp2 in particular
promotes the transport of phase II water-soluble drug metab-
olites, mainly sulfated, glucuronidated, and glutathione-conju-
gated drug metabolites. The bicyclic heptapeptide phalloidin is
a metabolically inert compound [23,40] and was also not
metabolized during our in situ excretion studies on rats and
mice (Fig. 5). Phalloidin is cationic with an estimated pKa above
14 [41] and is in this respect an exceptional Mrp2 substrate. It
should be seen as representing a new non-conjugated cyclic
peptide substrate of Mrp2, which may be added to another
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antagonist) [42], and to CCK-8, a linear peptide, that is also
transported by MRP2 [43,44].
A closer analysis of tissue concentrations of [3H]-DMP
revealed that DMP levels in livers from TR(−) rats were not
raised despite the lack of hepatobiliary elimination via Mrp2 and
markedly reduced excretion into bile. Because cell uptake via
Oatp1b2 still occurred, one would expect that hepatocytes from
TR(−) rats should become flooded by the phallotoxin, but this
was not observed. Instead, we have to assume that reflux via
basolateral efflux transporters prevented a rise of the intracel-
lular DMP content. As shown in Fig. 4, Mrp3 and Mrp4 were
expressed at higher levels in the livers of TR(−) rats. These
carriers could have accounted for an outwardly directed reflux of
phalloidin from hepatocytes into blood. Such upregulation of
efflux carriers in the basolateral membrane of hepatocytes was
previously reported as the explanation for liver-to-blood directed
secretion of pravastatin [45], gemfibrozil [46], and carboxydi-
chlorofluorescein diacetate [47] in TR(−) rats.
In contrast to bile, the urine of normal Wistar rats contained
only traces of 0.01% of the applied [3H]-DMP dose. In TR(−)
rats, however, a significant amount of the radioactivity (8.4%)
appeared in urine. An immediate explanation was that TR(−) rats
have compensated the disrupted hepatobiliary excretion route of
[3H]-DMP by higher renal carrier-mediated elimination. Since,
however, in the kidneys of TR(−) rats drug/toxin carrier mRNA
levels were not elevated when compared with Wistar rats, and
since in all mice strains very similar amounts of [3H]-DMP were
found in the urine, we conclude that the normal Wistar rat
exhibits an exceptional high first-pass elimination of DMP into
bile. This predominant and highly effective hepatobiliary elimi-
nation route in normal rats prevails over [3H]-DMP elimination
via the kidney. Because apart from liver selective Oatp1b2 no
other uptake carrier of phallotoxins is known, we assume that the
urinary excretion on TR(−) rats and mice is caused simply by
normal toxin filtration in the glomeruli.
Acknowledgments
The authors thank Kurt Stumpf for his excellent technical
help with the thin-layer chromatography of [3H]-DMP, Klaus
Schuh for his help in assisting at the cell preparations and
performing transport studies, and Kerstin Meerkamp for as-
sistance with the real-time PCR analysis. The authors also
would like to thank Michael Hanna, PhD, for proofreading the
manuscript. We are grateful to Prof. Dr. H. Faulstich who kindly
provided [3H]-DMP. This project was supported by the research
program Molecular Veterinary Medicine (GK 455), of the
Deutsche Forschungsgemeinschaft.References
[1] T. Wieland, O. Wieland, Chemistry and toxicology of the toxins of Amanita
phalloides, Pharmacol. Rev. 11 (1959) 87–107.
[2] E. Petzinger, M. Frimmer, Energy linked uptake of demethylphalloin by
isolated rat liver cells, Naunyn-Schmiedeberg's Arch. Pharmacol. 319
(1982) 87–92.[3] E. Petzinger, M. Frimmer, Driving forces in hepatocellular uptake of
phalloidin and cholate, Biochim. Biophys. Acta 778 (1984) 539–548.
[4] K. Münter, D. Mayer, H. Faulstich, Characterization of a transporting
system in rat hepatocytes. Studies with competitive and non-competitive
inhibitors of phalloidin transport, Biochim. Biophys. Acta 860 (1986)
91–98.
[5] A.M. Lengsfeld, I. Low, T.Wieland, P. Dancker,W. Hasselbach, Interaction
of phalloidin with actin, Proc. Natl. Acad. Sci. U. S. A. 71 (1974)
2803–2807.
[6] G. Gabbiani, R. Montesano, B. Tuchweber, M. Salas, L. Orci, Phalloidin-
induced hyperplasia of actin filaments in rat hepatocytes, Lab. Invest. 33 (1975)
562–569.
[7] T. Wieland, Modification of actins by phallotoxins, Naturwissenschaften
64 (1977) 303–309.
[8] W. Jahn, H. Faulstich, A. Deboben, T. Wieland, Formation of actin clusters
in rat liver parenchymal cells on phalloidin poisoning as visualized by a
fluorescent phallotoxin, Z. Naturforsch. 35 (1980) 467–469.
[9] H. Faulstich, K. Münter, D. Mayer, Phallodin action, in: D. Keppler, H.
Popper, L. Bianchi, W. Reutter (Eds.), Mechanisms of Hepatocyte Injury
and Death, MTP-Press, Lancaster, 1984, pp. 183–192.
[10] M. Frimmer, E. Petzinger, U. Rufeger, L.B. Veil, The role of bile acids in
phalloidin poisoning, Naunyn-Schmiedeberg's Arch. Pharmacol. 301 (1977)
145–147.
[11] E. Petzinger, Competitive inhibition of the uptake of demethylphalloin by
cholic acid in isolated hepatocytes. Evidence for a transport competition
rather than a binding competition, Naunyn-Schmiedeberg'sArch. Pharmacol.
316 (1981) 345–349.
[12] E. Petzinger, K. Ziegler, M. Frimmer, Inhibition of 3H-demethylphalloin
uptake in isolated rat hepatocytes under various experimental conditions,
Naunyn-Schmiedeberg's Arch. Pharmacol. 307 (1979) 275–281.
[13] M. Frimmer, E. Petzinger, K. Ziegler, Protective effect of anionic
cholecystographic agents against phalloidin on isolated hepatocytes by
competitive inhibition of the phallotoxin uptake. Comparison of the influence
on the inward transport of 3H-demethylphalloin and of 14C-cholate, Naunyn-
Schmiedeberg's Arch. Pharmacol. 313 (1980) 85–89.
[14] E. Petzinger, K. Ziegler, M. Frimmer, Occurrence of a multispecific
transporter for the hepatocellular accumulation of bile acids and various
cyclopeptides, in: G. Paumgartner, A. Stiehl, W. Gerok (Eds.), Bile acids
and the Liver, MTP-Press, Lancaster, 1987, pp. 111–124.
[15] M. Frimmer, K. Ziegler, The transport of bile acids in liver cells, Biochim.
Biophys. Acta 947 (1988) 75–99.
[16] B. Hagenbuch, P.J. Meier, The superfamily of organic anion transporting
polypeptides, Biochim. Biophys. Acta 1609 (2003) 1–18.
[17] V. Cattori, J.E. van Montfoort, B. Stieger, L. Landmann, D.K. Meijer, K.H.
Winterhalter, P.J. Meier, B. Hagenbuch, Localization of organic anion
transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate
specificity with Oatp1, Oatp2 and Oatp3, Pflügers Arch. 443 (2001)
188–195.
[18] J. König, Y. Cui, A.T. Nies, D. Keppler, A novel human organic anion
transporting polypeptide localized to the basolateral hepatocyte membrane,
Am. J. Physiol.: Gasterointest. Liver Physiol. 278 (2000) G156–G164.
[19] J.König,Y.Cui,A.T.Nies,D.Keppler, Localization andgenomic organization
of a new hepatocellular organic anion transporting polypeptide, J. Biol. Chem.
275 (2000) 23161–23168.
[20] T. Fehrenbach, Y. Cui, D. H.Faulstich, Characterization of the transport of
the bicyclic peptide phalloidin by human hepatic transport proteins,
Naunyn-Schmiedeberg's Arch. Pharmacol. 368 (2003) 415–420.
[21] F. Meier-Abt, H. Faulstich, B. Hagenbuch, Identification of phalloidin
uptake systems of rat and human liver, Biochim. Biophys. Acta 1664 (2004)
64–69.
[22] H. Puchinger, T. Wieland, 3H-desmethylphalloin, Liebigs Ann. Chem.
725 (1969) 238–240.
[23] H. Puchinger, T. Wieland, Search for some metabolites from poisoning by
desmethylphalloin (DMP), Eur. J. Biochem. 11 (1969) 1–6.
[24] C. Barriault, J.L. Petit, M. Gascon-Barre, P.M. Huet, I.M. Yousef, B.
Tuchweber, Effect of phalloidin on cholestasis, hemodynamics, and
microcirculation in isolated perfused rat liver, Hepatology 23 (1996)
294–302.
2077O. Gavrilova et al. / Biochimica et Biophysica Acta 1768 (2007) 2070–2077[25] A. Loranger, C. Barriault, I.M. Yousef, B. Tuchweber, Structural and
functional alterations of hepatocytes during transient phalloidin-induced
cholestasis in the rat, Toxicol. Appl. Pharmacol. 137 (1996) 100–111.
[26] C.C. Paulusma, M.A. van Geer, R. Evers, M. Heijn, R. Ottenhoff, P. Borst,
R.P. Oude Elferink, Canalicular multispecific organic anion transporter/
multidrug resistance protein 2 mediates low-affinity transport of reduced
glutathione, Biochem. J. 338 (1999) 393–401.
[27] K. Lischka, D. Starke, K. Failing, A. Herling, W. Kramer, E. Petzinger,
Hepatobiliary elimination of bile acid-modified oligodeoxynucleotides in
Wistar and TR- rats: evidence for mrp2 as carrier for oligodeoxynucleotides,
Biochem. Pharmacol. 66 (2003) 565–577.
[28] M. Dubin, M. Maurice, G. Feldmann, S. Erlinger, Phalloidin-induced
cholestasis in the rat: relation to changes in microfilaments, Gastroenterology
75 (1978) 450–455.
[29] J.A. Cooper, Effects of cytochalasin and phalloidin on actin, J. Cell Biol.
105 (1987) 1473–1478.
[30] D. Rost, J. Kartenbeck, D. Keppler, Changes in the localization of the rat
canalicular conjugate export pumpMrp2 in phalloidin-induced cholestasis,
Hepatology 29 (1999) 814–821.
[31] M. Ohashi, N. Sano, H. Takikawa, Effects of phalloidin on the biliary
excretion of cholephilic compounds in rats, Pharmacology 66 (2002)
31–35.
[32] T. Wieland, Amatoxins and phallotoxins — Structure and toxicity, in: V.
Voelter, G. Weitzel (Eds.), Structure and Activity of Natural Peptides,
Walter de Gruyter Publisher, Berlin, New York, 1981, pp. 23–40.
[33] I. Lorenzini, S. Sakisaka, P.J. Meier, J.L. Boyer, Demonstration of a
transcellular vesicle pathway for biliary excretion of inulin in rat liver,
Gastroenterology 91 (1986) 1278–1299.
[34] B.M. Johnson, P. Zhang, J.D. Schuetz, K.L. Brower, Characterization of
transport protein expression in multidrug resistance-associated protein
(mrp) 2-deficient rats, Drug Metab. Dispos. 34 (2006) 556–562.
[35] G.J. Hooiveld, J.E. van Montfoort, D.K. Meijer, M. Müller, Function and
regulation of ATP-binding cassette transport proteins involved in
hepatobiliary transport, Eur. J. Pharm. Sci. 12 (2001) 525–543.
[36] P. Chandra, K.L. Brouwer, The complexities of hepatic drug transport:
current knowledge and emerging concepts, Pharm. Res. 21 (2004) 719–735.[37] A. Haimeur, G. Conseil, R.G. Deeley, S.P. Cole, The MRP-related and
BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity
and regulation, Curr. Drug Metab. 5 (2004) 21–53.
[38] Y. Shitara, H. Sato, Y. Sugiyama, Evaluation of drug–drug interaction in
the hepatobiliary and renal transport of drugs, Annu. Rev. Pharmacol.
Toxicol. 45 (2005) 689–723.
[39] E. Petzinger, J. Geyer, Drug transporters in pharmacokinetics, Naunyn-
Schmiedeberg's Arch. Pharmacol. 372 (2006) 465–475.
[40] D. Rehbinder, O. G.Loeffler, T. Wieland, Studies on the mechanism of the
poisonous effect of phalloidin with poisons labelled with radioactive
substances, Hoppe Seylers Z.Physiol.Chem. 331 (1963) 132–142.
[41] E. Fürlinger, O.S. Wolfbeis, The absorption, fluorescence and phospho-
rescence of phalloidin and α-amanitin, Biochim. Biophys. Acta 760 (1983)
411–414.
[42] H.C. Shin, Y. Kato, T. Yamada, K. Niinuma, A. Hisaka, Y. Sugiyama,
Hepatobiliary transport mechanism for the cyclopentapeptide endothelin
antagonist BQ-123, Am. J. Physiol. 272 (1997) G979–G986.
[43] K. Letschert, M. Komatsu, J. Humel-Eisenbeis, D. Keppler, Vectorial
transport of the peptide CCK-8 by double transfected MDCKII cells stably
expressing the organic anion transporter OATP1B3 (OATP8) and the
export pump ABCC2, J. Pharmacol. Exp. Ther. 313 (2005) 549–556.
[44] K. Kopplow, K. Letschert, J. König, B. Walter, D. Keppler, Human
hepatobiliary transport of organic anions analyzed by quadruple-transfected
cells, Mol. Pharmacol. 68 (2005) 1031–1038.
[45] K.T. Kivistö, O. Grisk, U. Hofmann, K. Meissner, K.U. Möritz, C. Ritter,
K.A. Arnold, D. Lütjohann, K. von Bergmann, I. Klöting, M. Eichelbaum,
H.K. Kroemer, Disposition of oral and intravenous pravastatin in MRP2-
deficient TR- rats, Drug Metab. Dispos. 33 (2005) 1593–1596.
[46] M.S. Kim, D.Q. Liu, J.R. Strauss, I. Capodanno, Z. Yao, J.E. Fenyk-Melody,
R.B. Franklin, S.H. Vincent, Metabolism and disposition of gemfibrozil in
Wistar and multidrug resistance-associated protein 2-deficient TR- rats,
Xenobiotica 33 (2003) 1027–1042.
[47] M.J. Zamek-Gliszczynski, H. Xiong, N.J. Patel, R.Z. Turncliff, G.M.
Pollack, K.L. Brouwer, Pharmacokinetics of 5 (and 6)-carboxy-2′,7′-
dichlorofluorescein and its diacetate promoiety in the liver, J. Pharmacol.
Exp. Ther. 304 (2003) 801–809.
